An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation
Abstract
Without an effective prophylactic solution, infections from SARS-CoV-2 continue to rise worldwide with devastating health and economic costs. SARS-CoV-2 gains entry into host cells via an interaction between its Spike protein and the host cell receptor angiotensin converting enzyme 2 (ACE2). Disruption of this interaction confers potent neutralization of viral entry, providing an avenue for vaccine design and for therapeutic antibodies. Here, we develop single-domain antibodies (nanobodies) that potently disrupt the interaction between the SARS-CoV-2 Spike and ACE2. By screening a yeast surface-displayed library of synthetic nanobody sequences, we identified a panel of nanobodies that bind to multiple epitopes on Spike and block ACE2 interaction via two distinct mechanisms. Cryogenic electron microscopy (cryo-EM) revealed that one exceptionally stable nanobody, Nb6, binds Spike in a fully inactive conformation with its receptor binding domains (RBDs) locked into their inaccessible down-state, incapable of binding ACE2. Affinity maturation and structure-guided design of multivalency yielded a trivalent nanobody, mNb6-tri, with femtomolar affinity for SARS-CoV-2 Spike and picomolar neutralization of SARS-CoV-2 infection. mNb6-tri retains stability and function after aerosolization, lyophilization, and heat treatment. These properties may enable aerosol-mediated delivery of this potent neutralizer directly to the airway epithelia, promising to yield a widely deployable, patient-friendly prophylactic and/or early infection therapeutic agent to stem the worst pandemic in a century.
Competing Interest Statement
M.Schoof, B.Faust, R.Saunders, N.Hoppe, P.Walter, and A.Manglik are inventors on a provisional patent describing anti-Spike nanobodies described in this manuscript.
Subject Area
- Biochemistry (11493)
- Bioengineering (8567)
- Bioinformatics (28729)
- Biophysics (14724)
- Cancer Biology (11850)
- Cell Biology (17059)
- Clinical Trials (138)
- Developmental Biology (9273)
- Ecology (13965)
- Epidemiology (2067)
- Evolutionary Biology (18064)
- Genetics (12105)
- Genomics (16553)
- Immunology (11651)
- Microbiology (27517)
- Molecular Biology (11320)
- Neuroscience (59843)
- Paleontology (446)
- Pathology (1839)
- Pharmacology and Toxicology (3169)
- Physiology (4853)
- Plant Biology (10221)
- Synthetic Biology (2827)
- Systems Biology (7271)
- Zoology (1605)